Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotype serum levels in patients with rheumatoid arthritis following treatment with different biological drugs

Clinical and Experimental Rheumatology

Volumn 34, Issue 3, 2016, Pages 424-429

  Iannone, Florenzo ^a   Tampoia, Marilina ^b   Giannini, Margherita ^a   Lopalco, Giuseppe ^a   Cantarini, Luca ^c   Villalta, Danilo ^d   Galeazzi, Mauro ^c   Lapadula, Giovanni ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Anti CCP; DAS28; Rheumatoid factor IgA; Rheumatoid factor IgG; Rheumatoid factor IgM; Rituximab

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DAS28; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DRUG ADMINISTRATION; DRUG MONITORING; GENE REARRANGEMENT; IMMUNOLOGY; ITALY; LONGITUDINAL STUDY; PATIENT ACUITY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; BIOMARKERS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOLOGIC FACTORS; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT ACUITY; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; RITUXIMAB; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84980519025     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. DERGANOVA O, MARTINEZ-GAMBOA L, EGERER K, et al.: Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients. Clin Exp Rheumatol 2014; 32: 622-9.
2. KROL A, GARRED P, HEEGAARD N, et al.: Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis. Scand J Rheumatol 2015; 44: 8-12.
3. MEYER O, LABARRE C, DOUGADOS M, et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 120-6.
4. RANTAPää-DAHLQVIST S, de JONG B.A, BERGLIN E, et al.: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741-9.
5. SUN J, ZHANG Y, LIU L, LIU G: Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 2014; 32: 11-21.
6. VISSER H, le CESSIE S, VOS K, BREEDVELD FC, HAZES JM: How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
7. CAMBRIDGE G, LEANDRO MJ, EDWARDS JC, et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-54.
8. ARNETT FC, EDWORTHY SM, BLOCH DA, et al.: The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. LV Q, YIN Y, LI X, et al.: The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF-a agent treatment in patients with rheumatoid arthritis: a metaanalysis. PLoS One 2014; 9: e89442.
10. GARDETTE A, OTTAVIANI S, TUBACH F, et al.: High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis. Joint Bone Spine 2014; 81: 416-20.
11. TOUBI E, KESSEL A, SLOBODIN G, et al.: Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 818-20.
12. De RYCKE L, VERHELST X, KRUITHOF E, et al.: Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 299-302.
13. BOBBIO-PALLAVICINI F, CAPORALI R, ALPINI C, et al.: High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 302-7.
14. RöNNELID J, WICK MC, LAMPA J, et al.: Longitudinal analysis of citrullinated protein/ peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005; 64: 1744-9.